CommercialCoverageMedium impact
Genetic Testing for Cardiac Ion Channelopathies 2.02.38
Excellus BlueCross BlueShield·Cardiology, Family Medicine, Internal Medicine +1 more·Genetic Disease (Inherited Disease)
Effective date
May 21, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield updated their medical policy for genetic testing coverage for cardiac ion channelopathies, establishing specific criteria for when genetic testing for conditions like long QT syndrome, CPVT, Brugada syndrome, and short QT syndrome will be considered medically appropriate and covered.
Action Required
Before May 21, 2026: Billing team and providers must review patient documentation for genetic testing requests for cardiac ion channelopathies to ensure all specific clinical criteria are met and documented. Providers must document that test results will influence treatment decisions and verify family history requirements are met. Update prior authorization workflows to include these specific criteria for Excellus BlueCross BlueShield members.